基本信息
浏览量:7
职业迁徙
个人简介
We saw 800 brain tumor referrals and conducted 10-15 clinical trials annually. I also led the in vivo preclinical testing program which included 100 established CNS tumor cell lines and 50-60 patient-derived primary tumor xenografts. Each year we evaluated 50-75 investigational compounds for anti-tumor activity in flank and orthotopic, intracranial human brain tumor models. Via this effort, we successfully transitioned several preclinical compounds into clinical trials for brain tumor patients. I co-authored over 100 peer-reviewed manuscripts, was awarded an R21 NIH grant, and served as principal investigator of clinical core sections of an awarded brain SPORE grant and two program project grants. I also conducted several noteworthy, multi-center phase I-II clinical trials for neuro-oncology patients, two of which led to pivotal phase III studies evaluating cilengitide, as well as imatinib plus hydroxyurea, respectively, for glioblastoma. I also taught 1-3 neuro-oncology fellows per year who were supported through a NCI T-32 award. My clinical and research efforts at Duke were recognized by receipt of the R. K Rundles Award for Excellence in Clinical Oncology Research in 2007.
研究兴趣
论文共 791 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Neuro-oncologyno. 2 (2024): 211-225
Yu-Han Hung, Aparna Chhibber,Michael Lim,Michael Weller,David A. Reardon,Antonio Omuro, Keith L. Ligon, Ana Lako, Ann Forslund
Cancer Researchno. 7_Supplement (2024)
Steven Tobochnik, Maria Kristina C. Dorotan, Hia S. Ghosh,Emily Lapinskas, Jayne Vogelzang,David A. Reardon, Keith L. Ligon,Wenya Linda Bi, Stelios M. Smirnakis,Jong Woo Lee
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2024): 100697-100697
The Lancet. Oncologyno. 8 (2023): 925-935
FRONTIERS IN IMMUNOLOGYno. 7 (2023): 1297932-1297932
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
引用0浏览0引用
0
0
medRxiv (Cold Spring Harbor Laboratory) (2023)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn